Actively Recruiting

Age: 1Day - 25Years
All Genders
NCT05711992

Rare Embryonal Tumors of the Central Nervous System: International Registry

Led by Immune Oncology Research Institute · Updated on 2025-05-08

300

Participants Needed

11

Research Sites

521 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Central nervous system (CNS) tumors are the most common solid malignancies among children. Although some types of CNS tumors like medulloblastomas and low-grade gliomas are widespread and well-studied, there is a huge number of rare diseases that need further research. This international registry aims to establish a large multicenter database of pediatric and young adult patients with rare embryonal tumors of the central nervous system and describe the clinical presentations, diagnostics, treatment regimens, and outcomes. Embryonal tumors with multilayered rosettes (ETMR), FOXR2-activated CNS neuroblastoma, cribriform neuroepithelial tumor, and CNS tumor with BCOR internal tandem duplication are extremely rare embryonal tumors some of which were first described in the last edition of the World Health Organization (WHO) Classification of Tumors of the Central Nervous System. Objectives of the registry are 1) to evaluate prognostic factors, 2) to identify diagnostic and treatment gaps, 3) to investigate the characteristics and outcome of the disease with different treatment regimens, and 4) to generate data-based prospective diagnostic and treatment recommendations.

CONDITIONS

Official Title

Rare Embryonal Tumors of the Central Nervous System: International Registry

Who Can Participate

Age: 1Day - 25Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with rare embryonal tumors of the CNS since 01.01.2010, including ETMR (ETANTR, ependymoblastoma, medulloepithelioma), FOXR2-activated CNS neuroblastoma, cribriform neuroepithelial tumor, CNS tumor with BCOR internal tandem duplication, and patients diagnosed with neuroblastoma or ganglioneuroblastoma without molecular genetic tests
  • Patients aged 25 years or younger
  • Signed informed consent for prospective patients aged 18 years or older
  • Signed parental permission and child assent forms for prospective patients younger than 18 years
Not Eligible

You will not qualify if you...

  • CNS metastases of extracranial embryonal tumors

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 11 locations

1

Hematology Center named after prof. R. Yeolyan

Yerevan, Armenia, 0014

Actively Recruiting

2

Children's Hospital of Eastern Ontario (CHEO)

Ottawa, Canada, K1H 8L1

Actively Recruiting

3

Semmelweis University

Budapest, Hungary, 1085

Actively Recruiting

4

National Cancer Institute, All India Institutes of Medical Sciences

New Delhi, India, 110029

Actively Recruiting

5

Oncology Department of Golestan hospital

Tehran, Iran, 16686 19551

Actively Recruiting

6

IRCCS Istituto Ospedale Pediatrico Bambino Gesù

Rome, Italy, 00163

Actively Recruiting

7

Hospital Civil de Guadalajara "Dr. Juan I. Menchaca"

Guadalajara, Mexico, 44340

Actively Recruiting

8

Centro Médico ABC

Mexico City, Mexico, 01120

Actively Recruiting

9

Hospital Nacional Alberto Sabogal Sologuren - EsSalud

Bellavista, Peru, 07011

Actively Recruiting

10

Hospital Nacional Edgardo Rebagliati Martins

Lima, Peru, 15072

Actively Recruiting

11

China Medical University Children's Hospital

Taichung, Taiwan, 40447

Actively Recruiting

Loading map...

Research Team

J

Julieta Hoveyan, MD

CONTACT

R

Ruzanna Papyan, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here